Nexalin Technology, Inc. (NXL)
Nexalin Technology, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Houston, TX, US. The stock last traded at $0.36, up 1.03% on the session, giving a market capitalisation of $8.0M. On trailing twelve-month figures it carries a trailing P/E of -0.77, a net margin of -3022.9%. Its beta of 4.04 implies it has historically moved more than the broad market.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Nexalin Technology, Inc. is most often compared with the following Healthcare names: